GlaxoSmithKline is providing pandemic adjuvant technology to another company to bolster the chances of developing a vaccine against COVID-19.
Cambridge-based Magenta Therapeutics entered a non-exclusive research and clinical collaboration agreement with Beam Therapeutics.
Gilead Sciences entered into licensing agreements with five generic drugmakers to make the antiviral drug Veklury (remdesivir), the first medicine shown to be effective against COVID-19, available in 127 countries.
Moderna Inc. and Swiss contract drugmaker Lonza Group AG said on Friday they would accelerate the manufacturing of the U.S. drug developer’s potential coronavirus vaccine.
Veracyte Inc. and Yale University announced an exclusive licensing agreement to advance the first genomic test for predicting disease progression in patients with idiopathic pulmonary fibrosis (IPF).
Moderna Inc. announced an agreement for a commitment of up to $483 million from the Biomedical Advanced Research and Development Authority (BARDA) to accelerate development of the company’s mRNA vaccine candidate, mRNA-1273, against the novel coronavirus (SARS-CoV-2).
Waltham, Massachusetts-based TScan Therapeutics entered a collaboration agreement with Novartis to discover and develop novel T-cell Receptor (TCR)-engineered T-cell therapies for solid tumors.
Rockville, Md.-based Rexahn Pharmaceuticals terminated a nearly two-year-old agreement with Merck that paired the company’s experimental phosphorylated-p68 inhibitor with Keytruda as a potential treatment for metastatic triple-negative breast cancer.
Medidata, a global leader in creating end-to-end solutions to support the entire clinical trial process and a Dassault Systèmes company, announced that Medpace Inc. entered into an agreement to integrate Medidata Rave Imaging with Medpace’s imaging systems and workflow.
China’s Innovent Biologics forged a licensing agreement with biosimilar-focused Coherus BioSciences to commercialize Innovent’s biosimilar candidate to Avastin (bevacizumab) in the United States and Canada.
